A preliminary clinical trial to evaluate (64)Cu-NOTA-Trastuzumab as a positron emission tomography imaging agent in patients with breast cancer

BACKGROUND: The purpose of this study was to evaluate both the biodistribution and safety of (64)Cu-1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)-Trastuzumab, a novel (64)Cu-labeled positron emission tomography (PET) tracer for human epidermal growth factor receptor 2 (HER2) in patients with b...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Inki, Lim, Ilhan, Byun, Byung Hyun, Kim, Byung Il, Choi, Chang Woon, Woo, Sang-Keun, Kim, Kwang Il, Lee, Kyo Chul, Kang, Joo Hyun, Seong, Min-Ki, Kim, Hyun-Ah, Noh, Woo Chul, Lim, Sang Moo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818354/
https://www.ncbi.nlm.nih.gov/pubmed/33475899
http://dx.doi.org/10.1186/s13550-021-00746-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818354/
https://www.ncbi.nlm.nih.gov/pubmed/33475899
http://dx.doi.org/10.1186/s13550-021-00746-1

Ejemplares similares